Early data suggest that further increasing anti-tumour immune response with chemotherapy or immunotherapy drugs increase the anti-tumour effects of IL-1 targeted therapies further inhibiting bone metastasis and reducing soft tissue tumour burden, however, these are yet to be validated [5], [34]. The gene discussed is IL1A; the disease is neoplasm.